Alumis (ALMS) vs Verastem (VSTM)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 17, 2026.
Summary
Alumis (ALMS) has outperformed Verastem (VSTM) over the past year, gaining 32.8% versus a loss of 6.2%. Alumis is the larger company by market cap ($792.1 million vs $783.4 million), about 1.0 times the size. Verastem converts more of its revenue into profit, with a net margin of -677.6% versus -1011.7%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ALMS | VSTM |
|---|---|---|
| Share price | $6.12 | $8.65 |
| Market cap | $792.14M | $783.37M |
| 1-day change | -3.01% | -6.28% |
| YTD return | -37.30% | +12.05% |
| 1-year return | +32.75% | -6.18% |
| 5-year return | — | -71.73% |
| EPS (TTM) | $-3.86 | $-2.45 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $24.05M | $30.91M |
| Revenue growth (YoY) | — | +209.14% |
| Net income (latest FY) | $-243.32M | $-209.47M |
| Operating margin | -1886.92% | -550.33% |
| Net margin | -1011.75% | -677.59% |
| 52-week high | $31.35 | $10.82 |
| 52-week low | $4.37 | $3.43 |
| Distance from 52-week high | -80.48% | -20.06% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +408.66% | +90.06% |
| Average volume | 2.52M | 3.05M |
| Shares outstanding | 129.44M | 90.56M |
| Employees | 237 | 102 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ALMS has outperformed VSTM by 38.9 percentage points over the past year.
- Verastem is more profitable, keeping -677.6 cents of every revenue dollar as net income versus -1011.7 cents for Alumis.
About Alumis
ALMS stock →Alumis Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of medicines for autoimmune disorders. The company offers envudeucitinib, a tyrosine kinase 2 (TYK2) inhibitor for the treatment of plaque psoriasis and systemic lupus erythematosus; and A-005, a central nervous system-penetrant allosteric TYK2 inhibitor that is in Phase 1 for the treatment of neuroinflammatory and neurodegenerative diseases.
Health Care · Biotechnology: Pharmaceutical Preparations · 237 employees
About Verastem
VSTM stock →Verastem, Inc., a development-stage biopharmaceutical company, focuses on developing and commercializing drugs for the treatment of cancer in the United States. Its product candidates are Avutometinib, which is an orally administered, small molecule dual RAF/MEK inhibitor developed to block MEK kinase activity and the compensatory reactivation of MEK by upstream RAF, thereby targeting the RAS/MAPK signaling pathway that is commonly activated in various cancers; and Defactinib, an oral small molecule inhibitor of FAK and proline-rich tyrosine kinase for various solid tumors.
Health Care · Biotechnology: Pharmaceutical Preparations · 102 employees
ALMS vs VSTM FAQ
Which is bigger, Alumis or Verastem?
Alumis (ALMS) is larger, with a market capitalization of $792.14M compared with $783.37M for Verastem (VSTM).
Which stock has performed better over the past year, ALMS or VSTM?
ALMS returned +32.75% over the past 12 months, compared with -6.18% for VSTM (price return, excluding dividends). Past performance does not predict future results.
Are Alumis and Verastem in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.